State Street’s Avita Medical RCEL Stock Holding History

State Street’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$533K	Sell	128,977 -300,045	-70%	-$1.29M	﹤0.01%	3569
2026 Q1	$1.59M	Buy	429,022 +10,691	+3%	+$44.9K	﹤0.01%	3365
2025 Q4	$1.44M	Sell	418,331 -4,977	-1%	-$19.9K	﹤0.01%	3433
2025 Q3	$2.16M	Sell	423,308 -105,476	-20%	-$550K	﹤0.01%	3315
2025 Q2	$2.8M	Buy	528,784 +1,832	+0.3%	+$13.3K	﹤0.01%	3191
2025 Q1	$4.29M	Sell	526,952 -8,019	-1%	-$74.9K	﹤0.01%	2941
2024 Q4	$6.85M	Buy	534,971 +14,974	+3%	+$177K	﹤0.01%	2827
2024 Q3	$5.57M	Buy	519,997 +11,997	+2%	+$113K	﹤0.01%	2911
2024 Q2	$4.02M	Sell	508,000 -433,041	-46%	-$4.12M	﹤0.01%	3024
2024 Q1	$15.1M	Buy	941,041 +440,733	+88%	+$7.13M	﹤0.01%	2335
2023 Q4	$6.86M	Buy	500,308 +31,167	+7%	+$357K	﹤0.01%	2785
2023 Q3	$6.85M	Buy	469,141 +16,912	+4%	+$286K	﹤0.01%	2772
2023 Q2	$7.69M	Buy	452,229 +364,384	+415%	+$5.35M	﹤0.01%	2783
2023 Q1	$1.23M	Buy	87,845 +4,200	+5%	+$44.7K	﹤0.01%	3468
2022 Q4	$552K	Sell	83,645 -500	-0.6%	-$3K	﹤0.01%	3740
2022 Q3	$443K	Hold	84,145	–	–	﹤0.01%	3824
2022 Q2	$400K	Sell	84,145 -334,982	-80%	-$2.07M	﹤0.01%	3922
2022 Q1	$3.55M	Sell	419,127 -363,878	-46%	-$3.35M	﹤0.01%	3335
2021 Q4	$9.38M	Buy	783,005 +50,130	+7%	+$764K	﹤0.01%	2951
2021 Q3	$13M	Sell	732,875 -80,254	-10%	-$1.51M	﹤0.01%	2730
2021 Q2	$16.7M	Buy	813,129 +368,380	+83%	+$7.26M	﹤0.01%	2611
2021 Q1	$8.81M	Buy	444,749 +151,597	+52%	+$3.53M	﹤0.01%	2794
2020 Q4	$5.45M	Buy	+293,152	New	+$6.43M	﹤0.01%	2919

Other funds holding RCEL

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

State Street's RCEL Position: Q2 2026 in Review

State Street reduced its Avita Medical (RCEL) stake by 70% in Q2 2026, selling an estimated $1.29M and leaving 128,977 shares worth $533K. The position accounts for ﹤0.01% of the portfolio, ranked #3569.

State Street first reported a position in RCEL in Q4 2020 and has held it in 23 quarters since. The position peaked at $16.7M in Q2 2021. 74 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

State Street held 128,977 shares of Avita Medical worth $533K as of Q2 2026.
State Street sold 300,045 Avita Medical shares in Q2 2026, an estimated $1.29M.
Avita Medical made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3569 holding.
State Street first reported a position in Avita Medical in Q4 2020 and has held it in 23 quarters since.
State Street's Avita Medical position peaked at $16.7M in Q2 2021.
74 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.